CytoSurb

DGCI Approved Biocon's CytoSorb for COVID-19 Treatment

This is an extracorporeal blood purification (EBP) device which can help reduce pro-inflammatory cytokines levels in confirmed COVID-19 patients admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure. The Indian health regulator has granted licence to the company for emergency use of this device to treat COVID-19 patients who are 18 years of age or older. The licence will be valid until control of the COVID-19 outbreak in the country.